Date of filling in this questionnaire or last update: 05/06/2020
1. IDENTIFICATION & BASIC DESCRIPTION
Cohort name
  Nurses' Health Studies
Country
 

  • United States

Please provide any other information on the cohort location/s if needed
  Boston, MA
Name
  Heather Eliassen
Institution
  Channing Division of Network Medicine
Email
  heather.eliassen@channing.harvard.edu
Phone
  617-525-2279
Personal website
  http://researchfaculty.brighamandwomens.org/BRIProfile.aspx?id=1027
Do you want to add another Principal Investigator of the Cohort
 

  • Add another Principal Investigator of the cohort

Name
  Walter Willett
Institution
  Harvard T.H. Chan School of Public Health
Email
  walter.willett@channing.harvard.edu
Phone
  617-525-2279
Personal website
  https://www.hsph.harvard.edu/walter-willett/
Name
  Eva Schernhammer
Institution
  Channing Division of Network Medicine
Email
  eva.schernhammer@channing.harvard.edu
Phone
  617-525-4648
Personal website
  http://researchfaculty.brighamandwomens.org/BRIProfile.aspx?id=2306
Website
 

  • http://www.nurseshealthstudy.org/

Name of committee
  Brigham and Women's Hospital
Or provide website
 

  • http://www.nurseshealthstudy.org/

Contact Principal Investigator (name)
  Eva Schernhammer
Data access policy (briefly describe)
  https://www.nurseshealthstudy.org/researchers
Participation in pooled analyses
 

  • The cohort is potentially interested in participating in pooled analyses of (European) occupational cohort studies (note pooled analyses also includes remote decentralized analyses that would not require any transfer of primary data as well as meta-analyses).

Main aim of cohort, please briefly describe the main objectives of the cohort
  The primary motivation for the study was to investigate the potential long-term consequences of oral contraceptives, which were being prescribed to hundreds of millions of women.
Study design (please select as many as appropriate)
 

  • Prospective cohort

Source population (please select as many as appropriate)
 

  • Industry / occupation-based
  • Generation (parents-children) study

Comparators (please select as many as appropriate)
 

  • Internal study population

Enrollment
  Completed
Age range at entry (main cohort)
 

Minimum Maximum Mean
25 55

Women at enrollment
  238.000
Children (<18 years) at enrollment
  None
Men at last follow-up
  0
Women at last follow-up
  around 150.000
Children (<18 years) at last follow-up
  0
Participation rate at enrollment (if known)
  70
2. OUTCOME FOLLOW-UP
Type of data for outcome follow-up (please select as many as appropriate)
 

  • Active (contact with participants)
  • Death certificate
  • Hospital / physician diagnoses
  • Use of registers (specify)

Active (contact with participants) (specify)
 

  • Disease follow up based on self-report on questionnaire

Death certificate (specify)
 

  • National Death Index is searched regularly

Hospital / Physician diagnoses (specify)
 

  • Blinded physician code path reports for various disease outcomes

Specify: Use of registers
 

  • National Death Index to elicit deaths

First follow-up period (provide year)
  1976
Last follow-up period (provide year)
  2019
Number of follow-ups after baseline (provide number)
  Biennial, so up to 44 years i.e. 22 follow-ups
3. OCCUPATIONAL EXPOSURES
Source of exposure data collected (please select as many as appropriate)
 

  • Questionnaire, Personal (Self-reporting or interview)
  • Other (specify)

Specify: Other
  Blood and urine samples, saliva, toe nails
Occupational history/time frame
  Lifetime
Occupational coding performed
  No
Industry (specify coding system used)
 

  • All participants were registered nurses

Types of exposure measurements
 

  • Biomarkers (see also section 5)
  • Personal external sampling

Methods for exposure assessment (please select as many as appropriate)
 

  • Data modelling
  • GIS (other spatial methods)
  • Measurements (external sampling, biomarkers)
  • Self-report

Main categories
 

  • Physical agents
  • Psychosocial domains
  • Organisation of work including working time

Physical agents
 

  • Light-at-night (LAN)

Psychosocial domains | Job task characteristics/organization of work
 

  • Job control, autonomy
  • Psychological job demands

Organisation of work including working time | Shift work
 

  • Night (permanent or rotating)
  • Rotating (not night)

Organisation of work including working time | Working hours
 

  • Duration

4. OUTCOMES EVALUATED
Baseline - type of outcome data collected (select more than one if applicable)
 

  • Questionnaire, individual (self-recording or interview)

Follow-up - type of outcome data collected (select more than one if applicable)
 

  • Biomarker (specify)
  • Clinical/functional evaluation, e.g. spirometry, ECGs (specify)
  • Death certificates
  • Medical records
  • Questionnaire, individual (self-recording or interview)

Specify: Clinical/functional evaluation, e.g. spirometry, ECGs
  actigraphy
Specify: Biomarker
  blood and urine was collected twice
Outcome type (please select as many as appropriate)
 

  • Mortality
  • Morbidity

Diagnostic groups based on ICD10
 

  • C + D Neoplasms
  • D Diseases of blood and blood-forming organs excl. leukemia
  • E Endocrinological disease
  • E Malnutrition and obesity
  • E Metabolism disease
  • F Mental disorders
  • G Disease in the nervous system
  • H Disorders of the eye
  • H Disorders of the ear
  • I Heart disease
  • I Cerebrovascular diseases
  • J Respiratory disease
  • K Diseases of oral cavity, salivary glands and jaws
  • K Diseases of oesophagus, stomach, duodenum and appendix
  • K Hernia, colon and intestine disease
  • K Diseases of peritoneum, liver
  • L Skin, nail and hair disorders
  • M Arthritis, arthrosis, systemic connective disorders, spine disorders
  • M Disorders of muscles, bones, synovialis, bursa, cartilage
  • N Kidney, renal pelvis disease
  • N Male and female related disorders
  • O+P Pregnancy and labour
  • Q After birth – child disorders
  • S Injuries

C + D Neoplasms
 

  • Benign neoplasm
  • Carcinoma in situ
  • Leukemia
  • Malignant neoplasms gastro intes. system including liver, gall bladder, pancreas
  • Malignant neoplasm lung
  • Mesothelioma
  • Other malignant neoplasm of respiratory and intrathoracic organs, heart, pleura
  • Malignant neoplasm of bone and articular cartilage
  • Melanoma and other malignant neoplasms of skin
  • Neoplasms connective and soft tissue including nerves
  • Malignant neoplasm of breast
  • Malignant neoplasms, females gynecological
  • Malignant neoplasms of male genital organs
  • Malignant neoplasm of urinary tract and kidney
  • Malignant neoplasms of eye, brain and other parts of central nervous system
  • Malignant neoplasms of thyroid and other endocrine glands
  • Malignant neoplasms of ill-defined, secondary and unspecified sites
  • Malignant neoplasm without specification of site including excl. leukemia

D Diseases of blood and blood-forming organs excl. leukemia
 

  • Myelodysplastic syndromes
  • Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue
  • Sarcoidosis

E Endocrinological disease
 

  • Thyroidea
  • Diabetes mellitus

E Malnutrition and obesity
 

  • Deficiency of other B group vitamins
  • Vitamin D deficiency

E Metabolism disease
 

  • Hypercholesterolemia

F Mental disorders
 

  • Mood [affective] disorders
  • Depression
  • Eating disorders
  • Disorders of psychological development including autism and Aspergers syndrome

G Disease in the nervous system
 

  • Parkinson's disease
  • Sleep disorders

H Disorders of the eye
 

  • Glaucoma

H Disorders of the ear
 

  • Other, please state

H Disorders of the ear | Other (specify)
  Hearing loss
I Heart disease
 

  • Hypertensive diseases
  • Angina pectoris
  • Acute myocardial infarction
  • Chronic ischaemic heart disease
  • Pulmonary embolism

I Cerebrovascular diseases
 

  • Subarachnoid haemorrhage
  • Cerebral infarction
  • Stroke, not specified as haemorrhage or infarction
  • Aneurysm and dissection

J Respiratory disease
 

  • Vasomotor and allergic rhinitis
  • Chronic rhinitis, nasopharyngitis and pharyngitis
  • Chronic Bronchitis
  • Emphysema
  • Chronic obstructive pulmonary disease (COPD)
  • Asthma

K Diseases of oral cavity, salivary glands and jaws
 

  • Gingivitis and periodontal diseases
  • Other, please state

K Diseases of oral cavity, salivary glands and jaws | Other (specify)
  tooth loss
K Diseases of oesophagus, stomach, duodenum and appendix
 

  • Gastro-oesophageal reflux disease
  • Gastritis and duodenitis

K Hernia, colon and intestine disease
 

  • Crohn's disease
  • Ulcerative colitis
  • Diverticular disease of intestine
  • Irritable bowel syndrome

K Diseases of peritoneum, liver
 

  • Other, please state

K Diseases of peritoneum, liver | Other (specify)
  Liver cancer, gall stones
L Skin, nail and hair disorders
 

  • Atopic dermatitis
  • Psoriasis/Parapsoriasis
  • Sunburn
  • Alopecia areata
  • Acne
  • Vitiligo

M Arthritis, arthrosis, systemic connective disorders, spine disorders
 

  • Rheumatoid arthritis
  • Gout
  • Systemic lupus erythematosus

M Disorders of muscles, bones, synovialis, bursa, cartilage
 

  • Osteoporosis

N Kidney, renal pelvis disease
 

  • Renal failure

N Male and female related disorders
 

  • Hyperplasia of prostate
  • Male infertility
  • Endometriosis
  • Abnormal menstrual cycle
  • Female infertility
  • In vitro fertilisation
  • Spontaneous abortion

O+P Pregnancy and labour
 

  • Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium
  • Eclampsia in pregnancy, labour or puerperium
  • Diabetes mellitus in pregnancy
  • Preterm delivery
  • Extremely low birth weight
  • Other low birth weight
  • Exceptionally large baby

S Injuries
 

  • Injuries to the shoulder, arm and fingers
  • Injuries to the hip and thigh

Other health related outcomes
 

  • Biomarkers
  • Lifestyle change
  • Quality of life/wellbeing
  • Sleep
  • Work participation

5. BIOLOGICAL SAMPLES & ANALYSIS
Biological samples collected
 

  • Blood
  • Hair
  • Nails
  • Sputum
  • Urine

Biological processing
 

  • DNA
  • RNA

Genetic and other lab analyses
 

  • Biomarkers (specify)
  • Epigenomics
  • Genomics / GWAS
  • Metabolomics
  • Proteomics

Specify: Biomarkers
  Hormonal, inflammatory biomarkers, telomere length, and a wide range of other biomarkers have been measured over the years
6. Other Information
 

  • Alcohol
  • Anthropometry
  • Demographics
  • Diet
  • Education
  • Environmental, air pollution
  • Environmental other (specify)
  • Medical history
  • Personality
  • Physical exercise
  • Residential history
  • Socioeconomic status
  • Smoking

Specify: Environmental other
  LAN
Possibility for linkage to data registries/data enrichment via data linkage
 

  • Other (specify)

Specify: Other
  Medicaid
Please describe plans that are funded or most likely to be funded
  NHS3 is currently ongoing. Unlike NHS and NHS2, which were closed cohorts, NHS3 has ongoing enrollment and is purely online based. It also includes men, though the proportion of men is still very small. Currently, there are over 50.000 participants enrolled.